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The boom and bust cycle of 
biobanking – thinking through 
the life cycle of biobanks
The collection and use of tissue samples is by no means a 
new phenomenon (1,2). As an object of political interest 
and action, the international preoccupation and focus on 
biobanking has grown significantly in recent years. What 
has become more apparent is the quest to develop a more 
robust and systematized system for the collections, stor-
age, and distributions of tissue samples and the data that 
can be derived from them. From a policy perspective it is 
clear that biobanking has attracted a great deal of public 
funding in order to set up international networks of ex-
change between various actors. At the same time, howev-
er, the international boom associated with biobanks raises 
a number of important questions as to the development 
and sustainability of the field in the long run.
As part of the “Bio-objects” research network action sup-
ported by the European Cooperation in Science and Tech-
nology (COST) program, the Working Group on Generative 
Relations is interested in the different ways in which vari-
ous processes of bio-objectification become productive 
in society. In this sense, the role of biobanks as a nexus of 
productive capacity located between the populations and 
biomedical research is seen to be politically and scientifi-
cally crucial. During the past years, the interest to set up 
new biobanks in order to become a part of the develop-
ment of international networks for exchange and research 
has become evident (3), where national innovation and re-
search policies have played an important part in support-
ing such developments (4). There has also been a surge 
in the development of national systems for the collec-
tion and exchange of tissue samples and related material 
around the word. These processes include questions as to 
how to set up collection and storage facilities, what qual-
ity standards to use, as well as what types of pricing mod-
els should be implemented in order to keep the collection, 
storage, and distribution process sustainable.
With the surge in setting up new biobanks it is important 
to ask to what degree have those who are entrusted with 
managing these collections considered the long-term sus-
tainability of such collections when there is likely to be 
fierce competition among actors to collect and maintain 
their own collections. How many biobanks prepare for sit-
uations where the possibility of maintaining a collection 
becomes too expensive? What types of safeguards are in 
place to prepare for financial hardships, transfer of material 
and information to new actors, or the possibility of shut-
ting down of biobanks? To what degree do national fund-
ing organizations consider overlap?
LoNg-Term SuSTAiNAbiLiTy
The long-term policy goal associated with supporting 
biobanking activities and the development of biobank-
ing infrastructures throughout Europe relates to the de-
velopment of new innovations and business opportunities 
based on biobanking research. Diagnostics, pharmaceuti-
cal development, and therapeutics are only some of the 
areas to benefit from biobanking. It is, however, unclear to 
what degree national biobanking initiatives overlap and 
reproduce efforts, which are being undertaken in other 
countries and even within the same country. Although 
this can be argued to create a competitive environment, it 
also represents a waste of public funding and a situation 
in which the fate of many biobanks is tenuous at best. 
In many cases the long-term possibilities of running 
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biobanks will depend on the continued support of public 
funding organizations and institutions. It is unclear, how-
ever, to what extent various funding organizations and in-
stitutions, such as hospitals, will be willing to support such 
activities if there are few concrete returns.
The productivity of biobanks is another major problem 
facing the field in general. Although biobanks have exist-
ed for decades in various forms, it is only recently, with the 
political attention that they have gained, that the question 
of measuring productivity has come up. Increased public 
funding is followed by increased scrutiny over impact on 
society, still it is unclear how the productivity of biobanks 
should and could be measured. Should there be some 
form of Biobank Impact Factor (BIF) (5) or Bioresource 
research Impact Factor (BRIF) (gen2phen) that could be 
compared across borders, and in what ways would one 
measure different types of biobanks, such as stem cell 
banks, cord blood banks, epidemiological biobanks, and 
diagnostic biobanks?
Due to the infancy of the field in terms of translating re-
search into products, the benefits of biobanking are very 
difficult to operationalize in economic terms. DeCode Ge-
netics, for example, has been one of the leading companies 
in publishing high quality scientific articles, yet its track re-
cord in securing income from innovations is still very mod-
est in relation to the investment that has gone into its ac-
tivities. During times of economic recession and hardship, 
it is natural that public organizations, such as hospitals will 
pay close attention to the ways in which tax-payer mon-
ey is being spent and the impact that that money has on 
public health and medical practices.
WheN biobANkS fAiL
Inevitably, with such a large number of biobanks being es-
tablished, some will subsequently close, or be substantial-
ly reconfigured. This brings with it a particular set of ethi-
cal challenges that practitioners and social scientists must 
contend with (6), that should make a core contribution to 
any “sociology of biobanking” (7).
Cadigan et al (8) report examples of biobank managers 
who struggle with the discrepancy of hoping their bank 
will exist permanently while knowing their funding is lim-
ited. People in management positions are right to be 
aware of potential closure. Examples where this has al-
ready occurred within the private sector include Sera-
Care Life Sciences that sold its biobank in 2013 to re-
focus upon producing in vitro diagnostics products (9,10), 
Ardais that collapsed in 2005, selling on its biosamples to 
Cytomyx Holdings and its bespoke software to Gulfstream 
(11), and the Swedish project UmanGenomics that was 
mothballed in 2003 (12). Closures are not confined to the 
private sector, with public sector examples including the 
Massachusetts Stem Cell Bank that closed in 2012 (13), 
the Singapore Biobank and the US Armed Forces Institute 
of Pathology that closed in 2011 (14,15), and the UK Hu-
man Tissue Bank that closed in late 2009 (16). When these 
banks close the processes of bio-objectification they en-
gage in also breakdown as the value attached to the tis-
sue shifts in the absence of institutional structure, stan-
dards, and best practice.
Neil Stephens, co-author of this paper, has conducted em-
pirical work observing the closure of a biobank in real time. 
The biobank – which must remain anonymous due to the 
terms of the research – was established to both collect high 
quality disease specific human tissue and to operate as a 
focal point for developing national standards for best prac-
tice in the field. Initially well funded through governmental 
and charity sources, the biobank progressed well in negoti-
ating access to tissue with hospitals. However, over time ri-
gidities within these hospitals led to less tissue being deliv-
ered into the biobank than initially anticipated and, against 
a backdrop of increasing financial tightening, the funders 
decided to cease their support for biobanking activity. Like 
SeraCare Life Sciences, Ardais, and the US Armed Forces In-
stitute of Pathology, the biobank was then fragmented as 
parts of its tissue holding, computer software, and human 
resources were moved and reused in new biobanking con-
texts. It is clear that the boom and bust cycle of biobanking 
can bring institutions to an end. But it is also possible that 
after closure elements of a biobanking infrastructure can 
find a new use elsewhere.
As discreet entities biobanks perform a particular type of 
bio-objectification that brings together the sources of ma-
terial and information with users and refiners of that mate-
rial. At the same time, however, biobanks are supposed to 
exemplify one of the core suppositions of ideologies of the 
knowledge-based bio-economy where increasingly biologi-
cal resources can be exploited and developed to the benefit 
of society through the commercialization and commodifi-
cation of new types of products that become socially and 
economically productive. It is, however, unclear at this point 
to which degree bio-banks will be able to generate new 
knowledge on diseases that can be exploited and utilized in 
the health care sector and products and services.
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